Τίτλος:
Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Aims: To assess the effect of liraglutide on 24-hour ambulatory blood pressure and heart rate in patients with hypertension (pre- and stage 1 hypertension) and inadequately controlled Type 2 diabetes (glycated haemoglobin 7%–10% [53-86 mmol/mol]). Materials and methods: Eligible patients for this investigator-initiated, parallel-group, randomized, double-blind trial were on stable background antihyperglycaemic therapy excluding insulin, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors. Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg, titrated to 1.2 mg after the first week, or placebo for 5 weeks. The primary outcome was change in 24-hour ambulatory systolic blood pressure (SBP), and secondary outcomes included change in ambulatory diastolic blood pressure (DBP) and heart rate. We also assessed renal sodium handling. Results: Of 87 patients assessed for eligibility, 62 (66.1% men) with a mean age of 60.2 years were randomized to liraglutide (n = 31) or placebo (n = 31). All participants received background therapy with metformin, whilst 35.5% were treated concomitantly with sulphonylureas and 14.5% with pioglitazone. Compared with placebo, liraglutide reduced 24-hour SBP by −5.73 mm Hg (95% confidence interval [CI] –9.81 to −1.65) and had a neutral effect on 24-hour DBP (mean difference − 1.42 mm Hg; 95% CI –4.25 to 1.40), whilst increasing 24-hour heart rate by 6.16 beats/min (95% CI 3.25 to 9.07). Findings were consistent for daytime and night-time measurements. Liraglutide did not increase urine sodium excretion. Conclusion: Based on 24-hour ambulatory measurements, short-term treatment with liraglutide had a favourable effect on SBP whilst increasing heart rate. © 2018 John Wiley & Sons Ltd
Συγγραφείς:
Liakos, A.
Lambadiari, V.
Bargiota, A.
Kitsios, K.
Avramidis, I.
Kotsa, K.
Gerou, S.
Boura, P.
Tentolouris, N.
Dimitriadis, G.
Tsapas, A.
Περιοδικό:
Diabetes, Obesity and Metabolism
Εκδότης:
Wiley-Blackwell Publishing Ltd
Λέξεις-κλειδιά:
dipeptidyl peptidase IV inhibitor; glucagon like peptide 1 receptor agonist; glycosylated hemoglobin; insulin; liraglutide; metformin; pioglitazone; placebo; sulfonylurea derivative; lipid; liraglutide, adult; Article; blood pressure monitoring; controlled study; diastolic blood pressure; disease classification; drug dose comparison; drug dose titration; drug efficacy; female; heart rate; human; hypertension; major clinical study; male; non insulin dependent diabetes mellitus; outcome assessment; randomized controlled trial; sodium excretion; systolic blood pressure; treatment duration; urinary excretion; aged; blood; blood pressure; blood pressure monitoring; complication; double blind procedure; drug effect; glucose blood level; hypertension; middle aged; non insulin dependent diabetes mellitus; pathophysiology, Aged; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Lipids; Liraglutide; Male; Middle Aged; Placebos
